Taysha Shares Drop 9.8% on $200M Offering; Key Rett Syndrome Data Expected Soon
TSHA has more than doubled off its 52-week low of $2.25 on elevated volume (4.3× avg).
Summary
Taysha Gene Therapies priced a $200 million public offering of common stock and pre-funded warrants at $6.00 per share, expecting net proceeds of approximately $187.4 million. Shares fell 9.8% premarket following this news. This offering follows previous announcements and SEC filings regarding the proposed offering earlier this week. The offering is significantly dilutive, representing over 11% of the company's market capitalization, and the market has reacted negatively. Additionally, the company will present multiple data updates for its pivotal TSHA-102 program for Rett syndrome at a conference from June 29 to July 1. Investors will be focused on the TSHA-102 data presentation at the International Rett Syndrome Foundation meeting between June 29 and July 1.
At the time of this announcement, TSHA was trading at $6.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.25 to $7.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.